GB Sciences (GBLX) 10-Q/A 20 Aug 15 2016 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2015	Aug. 19, 2015
Document and Entity Information:
Entity Registrant Name	Growblox Sciences, Inc.
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Entity Central Index Key	1,165,320
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding		45,321,964
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	gblx

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($)	Jun. 30, 2015	Mar. 31, 2015
Current Assets
Cash and Cash Equivalents	$ 332,787
Accounts Receivable	50,000	$ 50,000
Prepaid Expenses	207,404	190,374
Total Current Assets	590,191	240,374
Property and Equipment, Net	1,067,920	913,642
Intangible Assets, Net	3,555	3,555
Other Assets
Deposits and Prepayments	298,637	293,920
Total Other Assets	298,637	293,920
Total Assets	1,960,303	1,451,491
Current Liabilities
Accounts Payable	664,270	677,230
Accrued Interest		230
Accrued Liabilities	102,341	72,776
Advance from Investor		150,000
Notes Payable		30,000
Deferred Compensation	1,632,754	1,522,537
Deferred Revenue	54,409	54,409
Total Current Liabilities	2,453,774	2,507,182
Other Long-Term Liabilities
Deferred Revenue	219,288	220,506
Other Long-Term Liabilities	754,968	654,968
Total Other Long-Term Liabilities	$ 974,256	$ 875,474
Commitments and Contingencies
Stockholders' Deficit
Common Stock	$ 4,532	$ 3,597
Deferred Stock Compensation	1,573,033	1,573,033
Additional Paid In Capital	12,436,398	10,751,690
Accumulated Deficit	(15,350,274)	(14,008,525)
Total Stockholders' Deficit	(1,336,311)	(1,680,205)
Non-controlling Interest	(131,416)	(250,960)
Total Deficit	(1,467,727)	(1,931,165)
Total Liabilities and Stockholders' Deficit	$ 1,960,303	$ 1,451,491

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Income Statement
Net revenue
General and administrative expenses	$ 1,522,765	$ 1,495,196
Loss from continuing operations	(1,522,765)	(1,495,196)
Other income/(expense)
Interest expense	(658)
Interest income		173
Other	1,219
Total other income/(expenses)	561	173
Net loss before non-controlling interest	(1,522,204)	(1,495,023)
Less: net loss attributable to non-controlling interests	(180,456)	(49,805)
Net Loss	$ (1,341,748)	$ (1,445,218)
Weighted average common shares outstanding - basic and diluted	41,026,532	3,658,004
Net loss per share - basic and diluted	$ (0.03)	$ (0.40)

STATEMENTS OF CASH FLOW

STATEMENTS OF CASH FLOW - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flow from operating activities:
Net Loss	$ (1,341,748)	$ (1,445,218)
Non-controlling interest	(180,456)	(49,805)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	43,519	287
Stock-based compensation	398,411	537,296
Recognition of Deferred Revenue	(1,218)
Changes in operating assets and liabilities:
Prepaids and other current assets	(21,747)	(20,664)
Accounts payable	(12,960)	14,100
Accrued interest	(230)
Accrued liabilities	29,565
Net cash used in operating activities	(1,086,864)	(964,004)
Cash flows from investing activities:
Increase in deposits	(4,717)
Purchase of property and equipment	(197,797)	(29,326)
Net cash used in investing activities	(202,514)	(29,326)
Cash flows from financing activities:
Cash from debt proceeds	100,000
Repayment of debt	(30,000)
Cash used to purchase warrants	(56,000)
Net proceeds from sale of stock	1,308,165	3,579,612
Stock subscription receivable		150,000
Stock subscription payable		25,250
Proceeds from noncontrolling interest	300,000	112,500
Net cash provided by financing activities	1,622,165	3,867,362
Net (decrease) increase in cash	332,787	2,874,032
Cash, beginning of year		339,327
Cash, end of year	332,787	3,213,359
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	526
Non-cash investing and financing activities:
Stock issued to settle advance	$ 150,000
Stock issued to settle convertible debt		893,831
Stock issued for intangible assets		$ 143,555

Note 1 - Organization and Princ

Note 1 - Organization and Principles of Consolidation	3 Months Ended
	Jun. 30, 2015
Notes
Note 1 - Organization and Principles of Consolidation	NOTE 1 – ORGANIZATION AND PRINCIPLES OF CONSOLIDATION Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2016. The balance sheet at March 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2015. Principles of Consolidation The consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. In our opinion, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation of the financial statements, have been included. Recent Developments On May 7, 2015, the Company entered into an agreement with Growblox Sciences, Puerto Rico, LLC, (“GBSPR”) a limited liability company organized under the laws of the Commonwealth of Puerto Rico. GBSPR is a related party through common equity ownership. The agreement grants GBSPR the exclusive worldwide rights to all Company technology and intellectual property to include, but not be limited to, the manufacture, the production, the lease and license of the Company’s indoor cultivation Suites and to sell to the Company for resale and distribution any and all pharmaceutical raw materials and products derived from medical-grade cannabis. All rights not granted to GBSPR under the agreement are retained by the Company and include the right to conduct pre-clinical and clinical trials; to develop formulations of combinations of active ingredients to combat specific conditions and diseases; and to sell, cultivate, grow, dispense medical-grade cannabis or cannabis in Nevada and Colorado. Terms of the agreement require GBSPR to obtain not less than $1,250,000 of equity financing by no later than September 30, 2015. Failing to do so would unilaterally terminate the agreement. On May 22, 2015, the Company received $300,000 of the partner equity financing proceeds. On May 12, 2015, the Company entered into a Note Purchase Agreement (“Note”) with Pacific Leaf Ventures, LP (“PLV”) whereby PLV agreed to make an installment loan to the Company of up to $1,750,000. The purpose of the financing is to provide for the acquisition and installation of an operating facility, equipment and other tangible assets of GB Sciences Nevada LLC, (“GBS”), a 65% subsidiary of the Company. The facility and equipment will be dedicated to the cultivation of cannabis and the extraction of oils and other constituents present in cannabis. The terms call for scheduled advances through August 2015, which will bear interest at a fixed rate of 6% per annum, payable quarterly. Principal payments are required on a quarterly basis in an amount equal to 50% of EBITDA of GBS multiplied by the Company’s percentage interest in GBS Nevada (currently 65%). All outstanding principal and interest is due and payable on May 12, 2020. While principal amounts remain outstanding under the Note, PLV or other Noteholders shall have the option to convert all or any portion of the outstanding principal amount of the Note into shares of common stock at a conversion price of $0.50, subject to adjustments for anti-dilution. The Company received loan installments of $100,000 on June 9, 2015, $200,000 on July 3, 2015, $200,000 on July 22, 2015 and $200,000 on August 3, 2015. The remaining installment is due by September 9, 2015. The timing of the installment advances were designed to fund the construction and implementation needs for the cultivation facility for GBS Nevada, thus the actual timing of said advances may vary. In a related development to the Note Purchase Agreement entered into May 12, 2015, PLV has entered into a Royalty Agreement which grants to the Company in perpetuity all of PLV’s intellectual property for the cultivation of cannabis and extraction of oils and other constituent chemicals for the sole use of GBS Nevada and its operations within the state of Nevada. In consideration, Growblox Sciences, Inc. is obligated to pay PLV for a period of five years, out of all periodic distributions it receives from GBS Nevada, the sum of $2.00 per gram of material extracted from cannabis at any facility owned, operated or controlled by GS plus 14% of the gross sales revenue. In years six through ten, the per gram payment will cease and the gross sales revenue percentage will be reduced to 7%. The gross sales revenue percentage is subject to equitable adjustments if the equity interest of the Company in GBS Nevada should change.

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Jun. 30, 2015
Notes
Note 2 - Going Concern	NOTE 2 – GOING CONCERN The Company’s financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since April 4, 2001, which losses have caused an accumulated deficit of approximately $15,350,000 at June 30, 2015. In addition, the Company has consumed cash in its operating activities of approximately $1,087,000 for the three months ended June 30, 2015 compared to $964,000 for the same period last year. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no assurances that the Company will be successful in achieving its goals. In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. .Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2015
Notes
Note 3 - Summary of Significant Accounting Policies	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents Property and Equipment Other Assets Revenue Recognition Research and Development Costs Equity-Based Compensation Income Taxes Loss per Share Use of Estimates. Reclassifications Fair Value of Financial Instruments. Fair Value Measurement FASB ASC 820 specifies a hierarchy of valuation techniques based upon whether the inputs to those valuation techniques reflect assumptions other market participants would use based upon market data obtained from independent sources (observable inputs). In accordance with FASB ASC 820, the following summarizes the fair value hierarchy: Level 1 Inputs—Unadjusted quoted market prices for identical assets and liabilities in an active market that the Company has the ability to access. Level 2 Inputs—Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3 Inputs—Inputs based on prices or valuation techniques that are both unobservable and significant to the overall fair value measurements. The Company did not identify any assets or liabilities that are required to be presented at fair value on a recurring basis. Carrying values of non-derivative financial instruments, including cash, accounts receivable, accounts payables, accrued expenses and other current liabilities, approximated their fair values due to the short maturity of these financial instruments. Recently Adopted Accounting Pronouncements.

Note 4 - Property and Equipment

Note 4 - Property and Equipment	3 Months Ended
	Jun. 30, 2015
Notes
Note 4 - Property and Equipment	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the asset or, in the case of leasehold improvements amortized over the lessor of the useful life of the asset or the underlying lease term. Property and equipment is comprised of computer equipment and software, other equipment and leasehold improvements.

Note 5 - Deferred Revenue

Note 5 - Deferred Revenue	3 Months Ended
	Jun. 30, 2015
Notes
Note 5 - Deferred Revenue	NOTE 5 – DEFERRED REVENUE On December 16, 2014, the Company entered into an agreement to license certain proprietary equipment to an entity that intends to market the service of isolating particular cannabis strains for the purpose of developing tissue from those strains so as to create a consistent, brandable product of the customer’s choosing from any such strain. The licensing agreement called for an initial non-refundable one-time license fee. The Licensee is entitled to sell this service to third parties nationwide for a term of five years. After recouping the one-time licensing fee, the Licensee is required to pay to the Company a royalty fee of 6% of the gross proceeds generated. The initial term will automatically renew for a period of three additional years, if certain minimum annual net sales are achieved. During the quarter ended June 30, 2015, the Company recognized approximately $1,200 in deferred revenue.

Note 6 - Capital Transactions

Note 6 - Capital Transactions	3 Months Ended
	Jun. 30, 2015
Notes
Note 6 - Capital Transactions	NOTE 6 – CAPITAL TRANSACTIONS In order to encourage the exercise of its B warrants, the board of directors passed a resolution to temporarily reduce the exercise price of such B warrants from $2.00 per share to $0.20 per share, and the holders of the B warrants were notified of such temporary exercise price reduction. As a result of this incentive, B warrants to purchase 2,160,112 shares of common stock were exercised at $0.20 per share, resulting in net proceeds of $432,022. On April 22, 2015, the Chief Executive Officer of Growblox Sciences Puerto Rico LLC, purchased 2,820,000 shares of common stock for $592,200 or $0.21 per share. Growblox agreed to register such common stock for resale under the Securities Act pursuant to a registration rights agreement. In addition, Growblox sold 1,995,833 shares of common stock to investors for $0.21 per share, resulting in total proceeds to Growblox of $419,225. Growblox issued 476,190 shares of common stock during the current quarter, the warrants of which were purchased in March 2015 for $0.21 per share, or $100,000.. Between February, 2015 and May 15, 2015, certain holders of B Warrants sold back to Growblox for $0.01 each, B warrants to purchase an aggregate of 1,600,000 shares of common stock. On April 27, 2015, two limited partnerships sold back to the Company for $0.01 each, warrants to purchase a total of 4,000,000 warrants for a total of $56,000. During the three months ended June 30, 2015, the Company issued an aggregate of 470,500 shares of common stock in settlement and release of certain obligations owed by the Company to various persons and recorded expenses of $152,430. The Company issued 424,400 shares of common stock to certain persons and employees and recorded an expense of $135,765. In May 2015, the Company issued 1,000,000 shares of common stock in connection with a cashless exercise of B warrants.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2015
Notes
Note 7 - Commitments and Contingencies	NOTE 7 – COMMITMENTS AND CONTINGENCIES On April 2, 2014, we commenced an action in the United States District Court for the Southern District of New York captioned Signature Exploration and Production Corporation v. GCM Administrative Services, LLC, Strategic Turnaround Equity Partners, L.P. (Cayman), Seth M. Lukash, and Gary Herman, 14 Civ. 02280 (ER) (the “Action”). After the change of name of Signature Exploration and Production Corporation, the caption was amended to substitute GrowBlox Sciences, Inc. as the plaintiff. The complaint in the Action sought a declaratory judgment that neither Lukash nor Herman was entitled to receive any interest in, including any shares of stock of, Growblox pursuant to certain share conversion rights held under promissory notes in the aggregate amount of $75,000, given by a related party of ours to the entity defendants GCM and Strategic. On May 9, 2014, defendants filed an answer denying the complaint’s material allegations, and asserted a counterclaim against us, against persons identified as certain of our officers or directors, and against GrowOpp, LLC and Tumbleweed Holdings, Inc. On November 19, 2014, defendants filed an amended counterclaim, including a prayer for monetary relief or damages in the sum of $9 million. We moved to dismiss the counterclaim and by opinion dated June 2, 2015, the Court granted the motion in part and dismissed counts one and two (for declaratory judgment as to an alleged partnership or joint venture, and for breach of fiduciary duty predicated upon those allegations), and denied the motion in part, leaving counts three and four of the counterclaim standing. The Court viewed the third and fourth claims as a single claim for unjust enrichment, in which recovery would be based on quantum merit, that is, upon the alleged value of any benefit conferred by defendants to us through alleged work and services rendered. In view of the fact that the pleading did not assign a particular value to that claim we are unable at present to advise what specific sum of money damages is sought. We did not challenge the fifth count of the counterclaim at this stage that seeks damages of $75,000 for alleged non-payment of the above-referenced promissory notes. The Company also become involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.

Note 1 - Organization and Pri12

Note 1 - Organization and Principles of Consolidation (Policies)	3 Months Ended
	Jun. 30, 2015
Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2016. The balance sheet at March 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2015.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. In our opinion, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation of the financial statements, have been included.

Note 3 - Summary of Significa13

Note 3 - Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2015
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents
Property and Equipment	Property and Equipment
Other Assets	Other Assets
Revenue Recognition	Revenue Recognition
Research and Development Costs	Research and Development Costs
Equity-based Compensation	Equity-Based Compensation
Income Taxes	Income Taxes
Loss per Share	Loss per Share
Use of Estimates	Use of Estimates.
Reclassifications	Reclassifications
Fair Value of Financial Instruments	Fair Value of Financial Instruments. Fair Value Measurement FASB ASC 820 specifies a hierarchy of valuation techniques based upon whether the inputs to those valuation techniques reflect assumptions other market participants would use based upon market data obtained from independent sources (observable inputs). In accordance with FASB ASC 820, the following summarizes the fair value hierarchy: Level 1 Inputs—Unadjusted quoted market prices for identical assets and liabilities in an active market that the Company has the ability to access. Level 2 Inputs—Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3 Inputs—Inputs based on prices or valuation techniques that are both unobservable and significant to the overall fair value measurements. The Company did not identify any assets or liabilities that are required to be presented at fair value on a recurring basis. Carrying values of non-derivative financial instruments, including cash, accounts receivable, accounts payables, accrued expenses and other current liabilities, approximated their fair values due to the short maturity of these financial instruments.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements.

Note 1 - Organization and Pri14

Note 1 - Organization and Principles of Consolidation (Details) - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	May. 12, 2015
Partner equity financing proceeds	$ 300,000	$ 112,500
Loan installments	$ 100,000
Growblox Sciences Puerto Rico LLC
Agreement Terms	Terms of the agreement require GBSPR to obtain not less than $1,250,000 of equity financing by no later than September 30, 2015. Failing to do so would unilaterally terminate the agreement.
Partner equity financing proceeds	$ 300,000
Pacific Leaf Ventures LP
Debt Instrument, Face Amount			$ 1,750,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Payment Terms	Principal payments are required on a quarterly basis in an amount equal to 50% of EBITDA of GBS multiplied by the Company’s percentage interest in GBS Nevada (currently 65%)
Debt Instrument, Maturity Date	May 12, 2020
Debt Instrument, Convertible, Conversion Price	$ 0.50
Royalty Agreement Description	Growblox Sciences, Inc. is obligated to pay PLV for a period of five years, out of all periodic distributions it receives from GBS Nevada, the sum of $2.00 per gram of material extracted from cannabis at any facility owned, operated or controlled by GS plus 14% of the gross sales revenue. In years six through ten, the per gram payment will cease and the gross sales revenue percentage will be reduced to 7%. The gross sales revenue percentage is subject to equitable adjustments if the equity interest of the Company in GBS Nevada should change.
Pacific Leaf Ventures LP | Loan Installment One
Loan installments	$ 100,000
Pacific Leaf Ventures LP | Loan Installment Two
Loan installments	200,000
Pacific Leaf Ventures LP | Loan Installment Three
Loan installments	200,000
Pacific Leaf Ventures LP | Loan Installment Four
Loan installments	$ 200,000
GB Sciences Nevada LLC
Subsidiary, Percentage Ownership	65.00%

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details) - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Details
Accumulated Deficit	$ (15,350,274)		$ (14,008,525)
Net cash used in operating activities	$ (1,086,864)	$ (964,004)

Note 3 - Summary of Significa16

Note 3 - Summary of Significant Accounting Policies: Loss per Share (Details) - shares	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Common stock
Potentially dilutive shares	41,026,532	29,520,288

Note 5 - Deferred Revenue (Deta

Note 5 - Deferred Revenue (Details) - USD ($)	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015
Deferred Revenue	$ 54,409	$ 54,409
Licensee
Royalty Agreement, Description	The licensing agreement called for an initial non-refundable one-time license fee. The Licensee is entitled to sell this service to third parties nationwide for a term of five years. After recouping the one-time licensing fee, the Licensee is required to pay to the Company a royalty fee of 6% of the gross proceeds generated. The initial term will automatically renew for a period of three additional years, if certain minimum annual net sales are achieved.
Deferred Revenue	$ 1,200

Note 6 - Capital Transactions (

Note 6 - Capital Transactions (Details) - Jun. 30, 2015 - USD ($)	Total
Cash used to purchase warrants	$ 56,000
Stock Sale 1
Stock Issued During Period, Value, New Issues	419,225
Stock Sale 2
Stock Issued During Period, Value, New Issues	100,000
Settlement of Obligations
Stock Issued During Period, Value, Conversion of Convertible Securities	152,430
Certain Persons and Employees
Stock Issued During Period, Value, New Issues	$ 135,765
Common stock | Stock Sale 1
Stock Issued During Period, Shares, New Issues	1,995,833
Share Price	$ 0.21
Common stock | Stock Sale 2
Stock Issued During Period, Shares, New Issues	476,190
Share Price	$ 0.21
Common stock | Settlement of Obligations
Stock Issued During Period, Shares, Conversion of Convertible Securities	470,500
Common stock | Certain Persons and Employees
Stock Issued During Period, Shares, New Issues	424,400
Common stock | Cashless Warrant Exercise
Stock Issued During Period, Shares, New Issues	1,000,000
Growblox Sciences Puerto Rico LLC | Chief Executive Officer
Stock Issued During Period, Value, New Issues	$ 592,200
Growblox Sciences Puerto Rico LLC | Chief Executive Officer | Common stock
Stock Issued During Period, Shares, New Issues	2,820,000
Share Price	$ 0.21
Class B Warrant
Exercise Price of Warrants	$ 0.20
Proceeds from Warrant Exercises	$ 432,022
Class B Warrant | Repurchase of Warrants 1
Share Price	$ 0.01
Warrants, Outstanding	1,600,000
Class B Warrant | Repurchase of Warrants 2
Share Price	$ 0.01
Warrants, Outstanding	4,000,000
Cash used to purchase warrants	$ 56,000

Note 7 - Commitments and Cont19

Note 7 - Commitments and Contingencies (Details)	3 Months Ended
	Jun. 30, 2015USD ($)
GCM and Strategic
Loss Contingency, Damages Sought, Value	$ 75,000